Teva, Sanofi score well with anti-TL1A drug in IBD test
The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent (dupilumab), which is approved across several indications, including atopic dermatitis, and is also in clinical testing for UC. Sanofi meanwhile also has a RIPK1 inhibitor, eclitasertib, in phase 2 for UC.
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...
Teva Pharmaceuticals is one of the best performing stocks in the SPDR S&P Pharmaceuticals ETF ( XPH) for 2024 as the stock ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
The dramatic rise is another peak in Teva's recovery over the past year and rewards investors after a long period of ...
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback